Drug Profile


Alternative Names: 80-574; 80/574; CDRI 80/574; CDRI 80574

Latest Information Update: 12 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Central Drug Research Institute
  • Developer Central Drug Research Institute; Zydus Cadila
  • Class Antihyperlipidaemics; Pregnadienes
  • Mechanism of Action Farnesoid X activated receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Hyperlipidaemia

Most Recent Events

  • 25 Aug 2015 Phase-III development for Hyperlipidaemia (Combination therapy) is ongoing in India
  • 11 Aug 2010 The programme is still in active development
  • 29 Oct 2009 This programme is still in active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top